Covalon Technologies Ltd. (CVE:COV – Get Free Report) reached a new 52-week low on Monday . The company traded as low as C$1.60 and last traded at C$1.60, with a volume of 1612 shares. The stock had previously closed at C$1.61.
Covalon Technologies Price Performance
The company has a market cap of C$44.42 million, a price-to-earnings ratio of 23.14 and a beta of 0.82. The company’s 50-day simple moving average is C$1.70 and its 200-day simple moving average is C$2.00. The company has a debt-to-equity ratio of 3.28, a current ratio of 7.27 and a quick ratio of 6.45.
About Covalon Technologies
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.
Featured Articles
- Five stocks we like better than Covalon Technologies
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Covalon Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covalon Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
